- Datum04.03.2026
- Uhrzeit13:00 - 14:00 Uhr
- Veranstalter
stock3
MannKind Corp. Chart inkl. Chartanalyse
Charts analysieren
wie die Profis?
Nutze unser Profi-Charting-Tool für Deine eigenen Analysen
Chart analysieren
Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate BSX | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
-3,13 %
Intraday
-46,93 %
1 Woche
-52,73 %
1 Monat
-48,15 %
Seit Jahresbeginn
-42,69 %
1 Jahr
-39,63 %
3 Jahre
-18,78 %
5 Jahre
-46,55 %
10 Jahre
Passender Service zu MannKind Corp.
Webinar zu MannKind Corp.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)2,830-6,510
- Jahrestief / Hoch ($)---
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von MannKind Corp.
Keine Dividenden verfügbar
Termine von MannKind Corp.
- Mai13MannKind Corp.Q1 2026 Earnings Release
- Aug12MannKind Corp.Q2 2026 Earnings Release
- Nov10MannKind Corp.Q3 2026 Earnings Release
Beschreibung
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
